Surgery, chemotherapy and radiotherapy have been the main pillars of cancer treatment. Some of the recent improvements in survival of other cancers can be attributed to novel treatment therapies. Such therapies mostly target specific molecules involved in cancer progression and metastasis. Development and clinical introduction of targeted therapies involve identification of new and potentially important molecules in cancer progression. The next important step is to evaluate its prognostic value. Prognostication by molecular markers is also important as this may identify subgroups of patients in need for additional treatment or not, which was not possible with the traditional clinic-pathological prognosticators. Hypoxic markers have been widely explored in the recent past for their prognostic efficacy in non-small cell lung cancer.
The present review article will enlighten importance of hypoxic markers with special reference to non-small cell lung carcinoma.Free PDF Download
To cite this article
F.-X. Xu, Y.-L. Zhang, J.-J. Liu, D.-D. Zhang, H.-B. Chen
Hypoxic markers in non-small cell lung cancer (NSCLC) – A review
Eur Rev Med Pharmacol Sci
Vol. 20 - N. 5